NSCLC patients with EGFR mutation(s) have been observed to have a higher response rate, longer progression-free survival and better tolerability to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) compared with standard first-line platinum-based doublet chemotherapy.3-5 In addition to prolonged progression-free survival, controlling the symptoms and improving the quality of life (QOL) of patients are also key goals in the treatment of advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.